LGALS9C

Summary

LGALS9C (galectin 9C, HGNC:33874) is a protein-coding gene on chromosome 17p11.2, encoding Galectin-9C (Q6DKI2). Binds galactosides.

This gene was initially thought to represent a pseudogene of galectin 9; however, this transcript has good exon-intron structure and encodes a predicted protein of the same size as and highly similar to galectin 9. This gene is one of two similar loci on chromosome 17p similar to galectin 9 and now thought to be protein-encoding. This gene is the more telomeric gene.

Source: NCBI Gene 654346 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 67 total — 2 pathogenic
• Phenotypes (HPO): 1
• Druggable target: yes
• MANE Select transcript: NM_001040078

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33874
Approved symbol	LGALS9C
Name	galectin 9C
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000171916
Ensembl biotype	protein_coding
Entrez	654346

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 6 protein_coding, 5 retained_intron, 4 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined

ENST00000328114, ENST00000577265, ENST00000577691, ENST00000578450, ENST00000578563, ENST00000578983, ENST00000579773, ENST00000580674, ENST00000581545, ENST00000582333, ENST00000582928, ENST00000583322, ENST00000584127, ENST00000584170, ENST00000584941, ENST00000892832

RefSeq mRNA: 1 — MANE Select: NM_001040078 NM_001040078

CCDS: CCDS32587

Canonical transcript exons

ENST00000328114 — 11 exons

Exon	Start	End
ENSE00002338734	18494221	18494945
ENSE00002730671	18476789	18476893
ENSE00003468982	18491945	18491989
ENSE00003478684	18488941	18489036
ENSE00003489067	18490733	18490768
ENSE00003541781	18492457	18492545
ENSE00003551689	18492697	18492859
ENSE00003555978	18487647	18487757
ENSE00003583482	18485934	18486135
ENSE00003614526	18483875	18483966
ENSE00003639363	18491273	18491323

Expression profiles

Bgee: expression breadth ubiquitous, 123 present calls, max score 92.55.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2393 / max 37.3791, expressed in 96 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159815	0.2393	96

Top tissues by expression

132 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
rectum	UBERON:0001052	92.55	gold quality
mucosa of stomach	UBERON:0001199	92.33	gold quality
mucosa of transverse colon	UBERON:0004991	88.79	gold quality
esophagus mucosa	UBERON:0002469	87.95	gold quality
lower esophagus mucosa	UBERON:0035834	85.50	gold quality
transverse colon	UBERON:0001157	82.59	gold quality
blood	UBERON:0000178	81.14	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.28	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.18	gold quality
gall bladder	UBERON:0002110	79.54	gold quality
body of stomach	UBERON:0001161	78.97	gold quality
colonic epithelium	UBERON:0000397	76.85	gold quality
stomach	UBERON:0000945	76.60	gold quality
granulocyte	CL:0000094	76.01	gold quality
duodenum	UBERON:0002114	75.70	gold quality
small intestine Peyer’s patch	UBERON:0003454	74.74	gold quality
small intestine	UBERON:0002108	74.48	gold quality
vagina	UBERON:0000996	71.16	gold quality
intestine	UBERON:0000160	69.85	gold quality
fundus of stomach	UBERON:0001160	69.72	gold quality
colon	UBERON:0001155	68.58	gold quality
spleen	UBERON:0002106	67.51	gold quality
esophagus	UBERON:0001043	64.91	gold quality
vermiform appendix	UBERON:0001154	64.30	gold quality
leukocyte	CL:0000738	64.16	gold quality
monocyte	CL:0000576	63.00	gold quality
lymph node	UBERON:0000029	62.72	gold quality
tonsil	UBERON:0002372	60.68	gold quality
ectocervix	UBERON:0012249	60.10	gold quality
right lobe of liver	UBERON:0001114	57.90	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.02
E-ENAD-17	no	11.30

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting LGALS9C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-8080	99.82	67.52	1342
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-1296-3P	99.72	64.04	636
HSA-MIR-10393-3P	99.72	66.56	961
HSA-MIR-6801-5P	99.72	66.50	981
HSA-MIR-20A-3P	99.44	69.10	1575
HSA-MIR-6744-3P	99.22	64.41	972
HSA-MIR-4757-5P	99.12	64.51	981
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-455-5P	98.74	67.31	795
HSA-MIR-6864-5P	98.38	66.59	1079
HSA-MIR-6880-5P	98.08	65.59	1282
HSA-MIR-204-3P	97.80	66.84	1656
HSA-MIR-4646-5P	97.70	66.84	1692
HSA-MIR-6857-3P	96.70	65.43	915
HSA-MIR-6782-5P	96.45	64.42	612
HSA-MIR-564	95.85	65.01	163
HSA-MIR-4693-3P	95.23	65.92	735

Literature-anchored findings (GeneRIF, showing 2)

• Functional analysis of the carbohydrate recognition domains and a linker peptide as to eosinophil chemoattractant activity (PMID:11971863)
• Specific recognition of Leishmania major poly-beta-galactosyl epitopes by this compound implicates it in interactions between L. major and host cells. (PMID:12684513)

Cross-species orthologs

23 orthologs

Organism	Symbol	Gene ID
danio_rerio	lgals3b	ENSDARG00000044001
danio_rerio	si:ch211-10a23.2	ENSDARG00000060656
danio_rerio	si:dkey-95h12.2	ENSDARG00000092923
drosophila_melanogaster	galectin	FBGN0031213
drosophila_melanogaster	CG11374	FBGN0031214
drosophila_melanogaster	CG13950	FBGN0031289
caenorhabditis_elegans		WBGENE00002264
caenorhabditis_elegans		WBGENE00002266
caenorhabditis_elegans		WBGENE00002269
caenorhabditis_elegans		WBGENE00002270
caenorhabditis_elegans		WBGENE00002271
caenorhabditis_elegans		WBGENE00004165
caenorhabditis_elegans	C27C7.5	WBGENE00007768
caenorhabditis_elegans	F46A8.3	WBGENE00009746
caenorhabditis_elegans	F46A8.4	WBGENE00009747
caenorhabditis_elegans	F46A8.5	WBGENE00009748
caenorhabditis_elegans	F46A8.8	WBGENE00009751
caenorhabditis_elegans		WBGENE00017080
caenorhabditis_elegans		WBGENE00018255
caenorhabditis_elegans		WBGENE00018649
caenorhabditis_elegans		WBGENE00018650
caenorhabditis_elegans		WBGENE00018651
caenorhabditis_elegans		WBGENE00235368

Paralogs (16): LGALS14 (ENSG00000006659), LGALS2 (ENSG00000100079), LGALS1 (ENSG00000100097), LGALS13 (ENSG00000105198), CLC (ENSG00000105205), LGALS8 (ENSG00000116977), LGALSL (ENSG00000119862), LGALS3 (ENSG00000131981), LGALS12 (ENSG00000133317), LGALS9 (ENSG00000168961), LGALS9B (ENSG00000170298), LGALS4 (ENSG00000171747), LGALS7B (ENSG00000178934), LGALS7 (ENSG00000205076), LGALS16 (ENSG00000249861), GRIFIN (ENSG00000275572)

Protein

Protein identifiers

Galectin-9C — Q6DKI2 (reviewed: Q6DKI2)

Alternative names: Galectin-9-like protein B

All UniProt accessions (8): Q6DKI2, J3KRF0, J3KSV0, J3KSY2, J3KT17, J3QKS2, J3QR96, J3QSH0

UniProt curated annotations — full annotation on UniProt →

Function. Binds galactosides.

Miscellaneous. The LGALS9-like proteins are encoded by a duplicated regions on chromosome 17; there are at least 3 genes coding for galectin-9-like proteins.

RefSeq proteins (1): NP_001035167* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001079	Galectin_CRD	Domain
IPR013320	ConA-like_dom_sf	Homologous_superfamily
IPR044156	Galectin-like	Family

Pfam: PF00337

UniProt features (11 total): sequence conflict 4, domain 2, binding site 2, chain 1, region of interest 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6DKI2-F1	84.74	0.77

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 82–88; 288–294

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 55 (showing top): GOBP_REGULATION_OF_CELL_ACTIVATION, GOBP_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_REGULATION_OF_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_LEUKOCYTE_PROLIFERATION, GOBP_NEGATIVE_REGULATION_OF_CELL_CELL_ADHESION, GOBP_CELL_CELL_ADHESION, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_CD4_POSITIVE_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_LEUKOCYTE_PROLIFERATION, GOBP_NEGATIVE_REGULATION_OF_TYPE_II_INTERFERON_PRODUCTION, GOBP_CYTOKINE_PRODUCTION, GOBP_REGULATION_OF_CD4_POSITIVE_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_NEGATIVE_REGULATION_OF_T_CELL_PROLIFERATION, GOBP_ALPHA_BETA_T_CELL_ACTIVATION, GOBP_LEUKOCYTE_CELL_CELL_ADHESION

GO Biological Process (3): positive regulation of gene expression (GO:0010628), negative regulation of type II interferon production (GO:0032689), negative regulation of CD4-positive, alpha-beta T cell proliferation (GO:2000562)

GO Molecular Function (3): galactoside binding (GO:0016936), carbohydrate binding (GO:0030246), protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), cytosol (GO:0005829)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	2
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
negative regulation of cytokine production	1
type II interferon production	1
regulation of type II interferon production	1
CD4-positive, alpha-beta T cell proliferation	1
negative regulation of alpha-beta T cell proliferation	1
negative regulation of CD4-positive, alpha-beta T cell activation	1
regulation of CD4-positive, alpha-beta T cell proliferation	1
carbohydrate derivative binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1054 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LGALS9C	HAVCR2	Q8TDQ0	999
LGALS9C	LAG3	P18627	991
LGALS9C	CLEC7A	Q9BXN2	983
LGALS9C	CTLA4	P16410	974
LGALS9C	TIGIT	Q495A1	950
LGALS9C	PDCD1	Q15116	947
LGALS9C	CD44	P16070	928
LGALS9C	CD274	Q9NZQ7	871
LGALS9C	TNFRSF9	Q07011	805
LGALS9C	BTLA	Q7Z6A9	799
LGALS9C	CEACAM1	P13688	796
LGALS9C	CD8A	P01732	778
LGALS9C	HSPB3	Q12988	764
LGALS9C	PTPRC	P08575	738
LGALS9C	TNFRSF14	Q92956	702

IntAct

101 interactions, top by confidence:

A	B	Type	Score
LGALS9C	PLSCR1	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	DAB1	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	RBPMS	psi-mi:“MI:0915”(physical association)	0.560
PLSCR1	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
RBPMS	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
QARS1	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
CYSRT1	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
KRTAP6-2	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	CASP6	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	CCK	psi-mi:“MI:0915”(physical association)	0.560
CRYAA	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
DYNC1H1	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	DNM2	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	ATN1	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C		psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	F13A1	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	GFAP	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	LAMP2	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	NDUFV2	psi-mi:“MI:0915”(physical association)	0.560
NOS3	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	PMP22	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	KLK6	psi-mi:“MI:0915”(physical association)	0.560
DNALI1	LGALS9C	psi-mi:“MI:0915”(physical association)	0.560
LGALS9C	BAG6	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (68): LGALS9C (Two-hybrid), LGALS9C (Two-hybrid), LGALS9C (Two-hybrid), LGALS9C (Two-hybrid), ATP2B4 (Affinity Capture-MS), RRAGC (Affinity Capture-MS), SLC12A2 (Affinity Capture-MS), SLC4A2 (Affinity Capture-MS), SLC4A7 (Affinity Capture-MS), ABCC4 (Affinity Capture-MS), SLC12A6 (Affinity Capture-MS), SLC12A4 (Affinity Capture-MS), SLC12A7 (Affinity Capture-MS), DAG1 (Affinity Capture-MS), LGALS9 (Affinity Capture-MS)

ESM2 similar proteins: A8MUM7, C0HJQ1, C0HJR3, O00182, O00214, O08573, O44126, O54891, O54974, O55060, P05162, P07583, P09382, P11116, P11762, P16045, P23668, P36573, P38552, P47929, P47967, P48538, P56217, P56470, P61801, P81184, P97590, P97840, Q05315, Q09581, Q1ECW6, Q29058, Q3B8N2, Q3MHZ8, Q3T0D6, Q49I35, Q504A5, Q5R7M1, Q62665, Q68FJ4

Diamond homologs: A4D1Z8, C0HJQ1, C0HJR3, O00182, O88644, P08699, P09382, P11116, P16110, P47953, P47967, P97840, Q3B8N2, Q3MHZ8, Q3T0D6, Q49I35, Q6DGJ1, Q6DKI2, Q9D1U0, A8MUM7, O08573, O54891, P38486, P38552, P47929, P79238, P97400, Q05315, Q29058, Q8K419, Q8TCE9, Q9UHV8, O00214, O44126, O54974, P07583, P08520, P17931, P23668, P47845

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

67 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	53
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2498730	GRCh37/hg19 17p11.2(chr17:17116969-20217378)x1	Pathogenic
545217	Single allele	Pathogenic

SpliceAI

1853 predictions. Top by Δscore:

Variant	Effect	Δscore
17:18476889:GCCCA:G	donor_gain	1.0000
17:18476894:G:GG	donor_gain	1.0000
17:18491269:CCAG:C	acceptor_loss	1.0000
17:18491270:CA:C	acceptor_loss	1.0000
17:18491271:A:AG	acceptor_gain	1.0000
17:18491271:AGAC:A	acceptor_loss	1.0000
17:18491272:G:GG	acceptor_gain	1.0000
17:18491322:CT:C	donor_gain	1.0000
17:18491323:TG:T	donor_loss	1.0000
17:18491324:G:GG	donor_gain	1.0000
17:18491325:TAAG:T	donor_loss	1.0000
17:18491990:G:GG	donor_gain	1.0000
17:18492455:A:AG	acceptor_gain	1.0000
17:18492455:AGCC:A	acceptor_gain	1.0000
17:18492456:G:GG	acceptor_gain	1.0000
17:18492456:GCC:G	acceptor_gain	1.0000
17:18492456:GCCG:G	acceptor_gain	1.0000
17:18492543:GAG:G	donor_gain	1.0000
17:18492861:TAA:T	donor_loss	1.0000
17:18494216:CACA:C	acceptor_loss	1.0000
17:18494218:CA:C	acceptor_loss	1.0000
17:18494220:G:GA	acceptor_loss	1.0000
17:18494220:GGT:G	acceptor_gain	1.0000
17:18494326:G:GT	donor_gain	1.0000
17:18494326:G:T	donor_gain	1.0000
17:18485925:T:TA	acceptor_gain	0.9900
17:18485926:G:A	acceptor_gain	0.9900
17:18485931:TAG:T	acceptor_loss	0.9900
17:18485995:C:A	acceptor_gain	0.9900
17:18486132:CAAGG:C	donor_loss	0.9900

AlphaMissense

2368 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:18492774:G:C	R280P	0.995
17:18492797:T:A	W288R	0.993
17:18492797:T:C	W288R	0.993
17:18492799:G:C	W288C	0.992
17:18492799:G:T	W288C	0.992
17:18492699:T:C	F255S	0.991
17:18492771:T:A	V279D	0.991
17:18492527:T:A	V248D	0.990
17:18492698:T:C	F255L	0.990
17:18492700:C:A	F255L	0.990
17:18492700:C:G	F255L	0.990
17:18492750:G:C	R272P	0.989
17:18492778:C:A	N281K	0.989
17:18492778:C:G	N281K	0.989
17:18492773:C:A	R280S	0.988
17:18492854:T:C	F307L	0.988
17:18492856:C:A	F307L	0.988
17:18492856:C:G	F307L	0.988
17:18492521:G:A	G246D	0.987
17:18485981:T:C	F60S	0.986
17:18492735:T:C	F267S	0.986
17:18492737:C:G	H268D	0.985
17:18486131:T:C	F110S	0.984
17:18485987:T:C	F62S	0.983
17:18487683:C:G	H124D	0.983
17:18492777:A:T	N281I	0.982
17:18483933:T:A	V33D	0.981
17:18487720:T:A	V136D	0.981
17:18486046:T:A	W82R	0.980
17:18486046:T:C	W82R	0.980

dbSNP variants (sampled 300 via entrez): RS1001084561 (17:18489256 A>C), RS1001470721 (17:18491740 G>A), RS1001523080 (17:18492323 T>A), RS1001807907 (17:18486906 A>G), RS1001858659 (17:18488414 T>TA), RS1003483567 (17:18482789 C>T), RS1003536196 (17:18483501 T>C), RS1005038138 (17:18481625 G>A), RS1005301716 (17:18475692 T>C), RS1005395669 (17:18480684 T>C), RS1006197486 (17:18487841 C>A,G,T), RS1006656757 (17:18493872 C>T), RS1007533480 (17:18475011 G>A), RS1008377682 (17:18490105 C>T), RS1008744772 (17:18489298 G>C)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:209850

GenCC curated gene-disease

Mondo (1): autism (MONDO:0005260)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000717	Autism

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D001321	Autistic Disorder	F03.625.164.113.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066211 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
GSK-J4	decreases expression	1
triphenyl phosphate	affects expression	1
perfluorooctanoic acid	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
perfluoro-n-nonanoic acid	decreases expression	1
perfluorohexanesulfonic acid	decreases expression	1
abrine	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Calcitriol	increases expression, affects cotreatment	1
Formaldehyde	decreases expression	1
Plant Extracts	affects cotreatment, decreases expression	1
Silicon Dioxide	decreases expression	1
Testosterone	affects cotreatment, increases expression	1
Tretinoin	increases expression	1
Triclosan	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5582103	Binding	Binding affinity to human galectin 9C by fluorescence anisotropy	Galectin-8N-Selective 4-Halophenylphthalazinone-Galactals Double π-Stack in a Unique Pocket. — ACS Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1G9	Abcam A-549 LGALS9C KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00211796	PHASE4	COMPLETED	Divalproex Sodium ER in Adult Autism
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT00409747	PHASE4	COMPLETED	Minocycline to Treat Childhood Regressive Autism
NCT00576732	PHASE4	COMPLETED	A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00844753	PHASE4	COMPLETED	Atomoxetine, Placebo and Parent Management Training in Autism
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01098383	PHASE4	UNKNOWN	Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02069977	PHASE4	UNKNOWN	Study to Evaluate the Efficacy and Safety of Aripiprazole
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02199925	PHASE4	UNKNOWN	An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02255565	PHASE4	COMPLETED	Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot Study
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT00036231	PHASE3	TERMINATED	Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction
NCT00036244	PHASE3	COMPLETED	Synthetic Human Secretin in Children With Autism
NCT00065884	PHASE3	UNKNOWN	Valproate Response in Aggressive Autistic Adolescents
NCT00065962	PHASE3	COMPLETED	Secretin for the Treatment of Autism
NCT00252603	PHASE3	COMPLETED	Galantamine Versus Placebo in Childhood Autism
NCT00346736	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00352248	PHASE3	COMPLETED	Randomized Controlled Trial of Acupuncture Versus Sham Acupuncture in Autistic Spectrum Disorder
NCT00352352	PHASE3	COMPLETED	Use of Acupuncture In Children With Autistic Spectrum Disorder
NCT00355329	PHASE3	COMPLETED	Randomized Control Trial of Using Tongue Acupuncture in Autistic Spectrum Disorder Using PET Scan for Clinical Correlation
NCT00498173	PHASE3	COMPLETED	Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism
NCT00541346	PHASE3	COMPLETED	A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms